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OBJECTIVES We sought to determine clinical and laboratory correlates of calcification of the coronary
arteries, aorta and mitral and aortic valves in adult subjects with end-stage renal disease
(ESRD) receiving hemodialysis.
BACKGROUND Vascular calcification is known to be a risk factor for ischemic heart disease in non-uremic
individuals. Patients with ESRD experience accelerated vascular calcification, due at least in
part to dysregulation of mineral metabolism. Clinical correlates of the extent of calcification
in ESRD have not been identified. Moreover, the clinical relevance of calcification as
measured by electron-beam tomography (EBT) has not been determined in the ESRD
population.
METHODS We conducted a cross-sectional analysis of 205 maintenance hemodialysis patients who
received baseline EBT for evaluation of vascular and valvular calcification. We compared
subjects with and without clinical evidence of atherosclerotic vascular disease and determined
correlates of the extent of vascular and valvular calcification using multivariable linear
regression and proportional odds logistic regression analyses.
RESULTS The median coronary artery calcium score was 595 (interquartile range, 76 to 1,600), values
consistent with a high risk of obstructive coronary artery disease in the general population.
The coronary artery calcium scores were directly related to the prevalence of myocardial
infarction (p  0.0001) and angina (p  0.0001), and the aortic calcium scores were directly
related to the prevalence of claudication (p  0.001) and aortic aneurysm (p  0.02). The
extent of coronary calcification was more pronounced with older age, male gender, white race,
diabetes, longer dialysis vintage and higher serum concentrations of calcium and phosphorus.
Total cholesterol (and high-density lipoprotein and low-density lipoprotein subfractions),
triglycerides, hemoglobin and albumin were not significantly related to the extent of coronary
artery calcification. Only dialysis vintage was significantly associated with the prevalence of
valvular calcification.
CONCLUSIONS Coronary artery calcification is common, severe and significantly associated with ischemic
cardiovascular disease in adult ESRD patients. The dysregulation of mineral metabolism in
ESRD may influence vascular calcification risk. (J Am Coll Cardiol 2002;39:695–701)
© 2002 by the American College of Cardiology
More than 350,000 persons in the U.S. have end-stage renal
disease (ESRD), and at least 10-fold more have a significant
degree of renal insufficiency (1,2). Cardiovascular disease
accounts for more than 50% of deaths among persons with
ESRD, and the annual cardiovascular mortality rate is more
than an order of magnitude greater than in the non-ESRD
population, especially among younger (70 years) individ-
uals (3). Certain factors have been proposed to contribute to
this exceptionally increased risk, including dyslipidemia,
hyperhomocysteinemia, oxidative stress of uremia and he-
modialysis, and the relatively infrequent use of aspirin,
beta-adrenergic antagonists, lipid-lowering agents, and es-
trogen replacement therapy in this population (4–10).
Recently, interest has focused on the roles of hyperphos-
phatemia, elevated levels of the calcium x phosphorus
product and hyperparathyroidism in the development of
cardiovascular disease in ESRD. Goodman et al. (11)
recently demonstrated a high prevalence of coronary artery
calcification among young adults receiving dialysis, espe-
cially those who had been receiving dialysis for more than 10
years.
In the context of a randomized clinical trial comparing
two classes of phosphate binders, we obtained baseline
electron-beam tomography (EBT) scans on 205 patients
receiving maintenance hemodialysis. The main goals of this
analysis were to determine whether cardiovascular disease
was related to the vascular calcification scores derived by
EBT and to determine clinical correlates of the extent of
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coronary artery, aortic and valvular calcification in this
population.
METHODS
Subjects. Subjects were adult (age 18 years) patients
receiving maintenance hemodialysis enrolled in a random-
ized clinical trial comparing calcium-based phosphate bind-
ers (calcium carbonate or calcium acetate) with sevelamer
hydrochloride, a non-calcium, non-aluminum-containing
polymer. There were 15 participating dialysis centers: seven
in the U.S. and eight in western Europe. Subjects with the
following history were excluded from participation: serious
gastrointestinal disease (including dysphagia, active un-
treated gastroparesis, severe motility disorder, major intes-
tinal surgery, markedly irregular bowel function), ethanol or
drug dependence or abuse, active malignancy, HIV infec-
tion, vasculitis, severe hyperphosphatemia (defined as con-
sistently having a serum phosphorus concentration 8.0
mg/dL, due to poor adherence with phosphate binders), or
those whose diabetes mellitus or hypertension was so poorly
controlled as to interfere with the conduct of the study as
deemed by the investigator. Baseline data on demographic,
dialysis-specific and clinical characteristics were obtained, as
were a variety of biochemical parameters (including serum
phosphorus, calcium, intact parathyroid hormone [PTH],
and total, high-density and low-density lipoprotein choles-
terol [HDL and LDL], and triglycerides). The LDL level
was calculated using Friedewald’s formula (12). Atheroscle-
rotic vascular disease (ASVD) was documented by the
clinical diagnoses of coronary artery disease (CAD) (a
history of myocardial infarction [MI] or angina pectoris, or
evidence of obstructive disease by angiography), cerebrovas-
cular disease (a history of thrombotic stroke or transient
ischemic attack) and peripheral vascular disease (a history of
claudication, lower extremity revascularization or aortic
aneurysm). Written informed consent was obtained from all
subjects. The study was conducted in compliance with the
recommendations of the Committees on Human Research
at each of the participating medical centers (see Appendix).
Imaging procedure. All subjects underwent an EBT im-
aging procedure on a C-100 or C-150 scanner (Imatron;
South San Francisco, California). Imaging was performed
with a 100-ms scanning time and a single-slice thickness of
3 mm. Thirty-six to 40 tomographic slices were obtained for
each subject during two breath-holding periods for the
C-100 scanner and a single breath-holding period for the
C-150 scanner. Tomographic imaging was electrocardio-
graphically triggered at 60% or 80% of the R-R interval
(according to each individual imaging center’s protocol) and
proceeded from the level of the carina to the diaphragm.
Thus, this imaging protocol prevented the visualization of a
portion of the aortic arch. All areas of calcification with a
minimal density of 130 Hounsfield units within the borders
of the coronary arteries, aorta, mitral and aortic valves were
computed. A calcified plaque was considered present if at
least three contiguous pixels with a density of 130
Hounsfield units were measured (an area equivalent to
1.03 mm2). The radiation exposure from one EBT scan is
approximately 1 rem.
The acquired images were reviewed on a NetraMD
workstation (ScImage; Los Altos, California). The total
volume and density of calcification were derived in the
following areas: 1) coronary arteries (left main, left anterior
descending, left circumflex and right coronary artery); 2)
aorta (with the exclusion of the top portion of the aortic
arch that was not included because of the imaging protocol
used); and the 3) mitral and 4) aortic valves. The calcium
score originally described by Agatston et al. (13) was
calculated. The “Agatston score” incorporates the density of
calcification, multiplying the calcification volume by a
weighted density coefficient (13).
Scans were considered of acceptable research quality only
if the images were free from artifacts due to motion,
respiration or asynchronous electrocardiographic triggering.
Repeat scanning was required in only one case. To ensure
the continuity and consistency of the calcium score inter-
pretation, a single expert investigator unaware of the sub-
jects’ clinical status reviewed all EBT scans.
Statistical analysis. For descriptive purposes, subjects were
classified into four coronary calcification groups: none (cal-
cium score  0), mild to moderate (calcium score  1 to
400), severe (calcium score  401 to 1,000) and very severe
(calcium score 1,000). This classification is a modification
of the categorization proposed by Rumberger et al. (14),
who recommended dividing coronary artery calcification
scores into four categories. Calcium scores 10 indicate the
presence of minimal atherosclerotic plaque. Calcification
scores between 11 and 100 indicate mild plaque burden.
These two groups experience a low likelihood of obstructive
CAD. Calcium scores between 101 and 400 indicate mod-
erate plaque burden and a relatively high likelihood of
CAD. Finally, calcium scores 400 indicate severe and
extensive atherosclerotic disease. Patients with calcification
scores in this range are very likely to have obstructive CAD,
with a high risk of developing symptomatic myocardial
ischemia (14). For this study, the classification was modified
to accommodate the more extensive degree of calcification
observed in the hemodialysis population. Therefore, the
mild and moderate categories were combined into a single
category. Additionally, a fourth category, “very severe,” was
Abbreviations and Acronyms
ASVD  atherosclerotic vascular disease
CAD  coronary artery disease
EBT  electron-beam tomography
ESRD  end-stage renal disease
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MI  myocardial infarction
PTH  parathyroid hormone
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created to categorize those subjects with markedly elevated
calcium scores.
Baseline characteristics were described using conventional
descriptive statistics such as mean  standard deviation,
median  interquartile range and proportions. Correlation
between sites of calcification was described with the Spear-
man correlation coefficient. To evaluate whether EBT had
prognostic value in the hemodialysis population, we used
the Wilcoxon rank sum test to examine the associations
among coronary artery and aortic calcium scores with
cardiovascular (i.e., MI, angina pectoris) and peripheral
vascular disease (i.e., claudication or lower extremity revas-
cularization, aortic aneurysm) outcomes. Linear regression
analysis was conducted in the 170 subjects with evidence of
coronary artery calcification (and the 164 subjects with
evidence of aortic calcification), to investigate whether the
extent of calcification was related to any demographic,
clinical or laboratory variables. The calcium scores were
highly right-skewed, and therefore, log-transformed prior
to inference testing. Age, gender, race, diabetes and dialysis
vintage (time since the initiation of dialysis) were included
in all models. Smoking status, vitamin D usage, prior
parathyroidectomy, and screening serum albumin, hemo-
globin, phosphorus, calcium, PTH, and lipids (total, HDL,
LDL cholesterol and triglycerides) were candidate variables
in multivariable analyses. Variables denoting the presence or
absence of vascular disease were not included in the model
building process, as they may have resulted from, rather
than caused, calcification. As a confirmatory approach, we
used proportional odds logistic regression to estimate the
associations among categories of calcium score and candi-
date explanatory variables. This approach allowed the in-
clusion of all subjects. The proportional odds assumption
was tested and deemed non-significant using the Score test
(15).
All reported p values are based on two-tailed tests of
statistical significance. Analyses were conducted using SAS
6.12 (SAS Institute; Cary, North Carolina).
RESULTS
Baseline subject characteristics are outlined in Table 1.
Demographic characteristics of the study sample were sim-
ilar to the general ESRD population in the U.S. and
Europe. Calcification of the coronary arteries, aorta and
mitral and aortic valves was frequent and severe (see below).
Figure 1 shows an example of calcium deposition in the
coronary arteries of an asymptomatic individual extracted
from the general population (Fig. 1A) and a subject with
ESRD (Fig. 1B).
Correlation between EBT-measured calcification and
coronary heart disease/peripheral vascular disease. The
coronary artery calcium scores were directly related to the
prevalence of coronary, cerebral and peripheral vascular
disease in the study subjects. Figure 2 shows the prevalence
of ASVD by calcium score category. Tables 2 and 3 show
the proportion of subjects in each calcium score category
with prevalent vascular disease.
Coronary artery calcification. The median coronary artery
calcium score was 595 (interquartile range, 76 to 1,600).
Fewer than one in five subjects (17%) had no evidence of
coronary calcification. More than 70% of subjects had scores
above the 75th percentile for age- and gender-matched
persons without ESRD. A score greater than the 75th
percentile has been shown to be associated with a high risk
of future MI and coronary death in the general population
(16).
Table 4 shows the linear regression results. Calcification
was more pronounced with older age, male gender, non-
black race, diabetes, longer dialysis vintage and higher
serum concentrations of calcium and phosphorus. This
model explained 36% of the variance in coronary artery
calcification. Notably, tobacco use, lipids, PTH, and serum
albumin and hemoglobin (markers of overall health in the
hemodialysis population) were not significantly related to
the extent of coronary artery calcification. Since age, gender,
race, diabetes and vintage are immutable, it is worth
considering the associations of serum calcium and phospho-
rus on calcification relative to these other factors. For
example, a 1-mg/dl higher serum calcium value corresponds
to the same increase in calcification as more than five years
(63.5 months) of receiving dialysis; a 1-mg/dl higher serum
Table 1. Baseline Characteristics of Study Subjects (n  205)
Characteristics Data
Age (yr) 56.8  14.9
Gender (% female) 35.6%
Race (% black) 17.6%
Diabetes (%) 29.8%
Dialysis vintage* (mo, median, interquartile range) 36.8 (17.1 to 62.5)
Presumed cause of ESRD (%)
Diabetes 23.5%
Hypertension 17.2%
Glomerulonephritis 22.1%
Polycystic kidney disease 10.3%
Interstitial nephritis 4.9%
Other 22.1%
Current smoking (%) 8.3%
History of kidney transplantation (%) 15.3%
History of parathyroidectomy (%) 7.4%
Vitamin D usage (%) 52.5%
Albumin (g/dl) 3.9  0.2
Hemoglobin (g/dl) 11.6  1.3
Albumin-adjusted calcium (mg/dl) 9.6  0.7
Phosphorus (mg/dl) 5.7  1.4
Calcium  phosphorus (mg2/dl2) 55.1  13.5
Intact PTH (pg/ml, median, interquartile range) 145 (67 to 268)
Total cholesterol (mg/dl)† 185.4  40.9
HDL cholesterol (mg/dl) 45.4  14.5
LDL cholesterol (mg/dl) 103.3  33.3
Triglycerides (mg/dl) 195.7  169.2
*Full range of dialysis vintage 1.9 to 310.7 months, or 0.2 to 25.9 years. †HMG-CoA
reductase inhibitors prescribed in 28.5%, fibrates prescribed in 0.5% of subjects.
ESRD  end-stage renal disease; HDL  high-density lipoprotein; LDL 
low-density lipoprotein; PTH  parathyroid hormone.
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phosphorus corresponds to the same increase in calcification
as nearly 21⁄2 years (28.8 months).
Proportional odds logistic regression confirmed these
findings, as the odds of being in higher categories of
calcification increased significantly with older age (p 
0.02), male gender (p  0.02), diabetes (p  0.01), longer
Figure 1. The subject in A is a 68-year-old healthy female volunteer with calcification in the middle left anterior coronary artery (white arrow) and a total
coronary artery calcium score of 45 (approximately 50th percentile for age and gender). The patient with end-stage renal disease in B is a 70-year-old woman
with extensive calcification in the middle and distal left anterior coronary artery (black arrow). The coronary artery calcium score was 374, corresponding
to 90th percentile for age and gender.
Figure 2. The prevalence of atherosclerotic vascular disease by coronary artery calcium score category. ASVD  atherosclerotic vascular disease.
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dialysis vintage (p  0.0001) and higher concentrations of
calcium (p 0.009) and phosphorus (p 0.01). Non-black
race was of borderline significance (p  0.07).
Aortic calcification. The median aortic calcium score was
629 (interquartile range, 25 to 3,662). Subjects with clau-
dication (p  0.001) and a known aneurysm (p  0.02) had
significantly higher aortic calcium scores than subjects
without these conditions.
Multivariable linear regression analysis was conducted
using the log-transformed aortic calcium score as the
dependent variable. When added individually to the core
model (age, age squared, gender, race, diabetes and dialysis
vintage), serum phosphorus (p  0.007) and PTH (p 
0.006) were significantly associated with aortic calcification,
although serum calcium (p  0.92) was not. Table 5 shows
the multivariable linear regression results, adjusting simul-
taneously for these factors. The model R2 was 0.50. In
contrast to the coronary artery model, gender and diabetes
were not significantly associated with the extent of aortic
calcification.
There are no conventional methods of categorizing pa-
tients by aortic calcium score. Using tertiles of aortic
calcification, the proportional odds regression analysis con-
firmed the linear regression findings. Older age (p 0.002),
non-black race (p  0.0008), longer dialysis vintage (p 
0.0007) and higher concentrations of serum phosphorus
(p  0.03) and PTH (p  0.03) were significantly associ-
ated with higher tertiles of aortic calcification.
Mitral and aortic valve calcification. Valvular calcification
was less frequent than vascular calcification in general.
Nevertheless, the prevalence and extent of valvular calcifi-
cation were remarkable. Forty-five percent of subjects had
calcification of the mitral valve, and 34% of subjects had
calcification of the aortic valve, compared with an expected
prevalence of 3% to 5% in the general population (17).
Twenty-one percent of subjects had calcification of both
valves. Aortic and mitral valve calcification scores were
directly but relatively weakly correlated with each other
(Spearman r  0.30, p  0.0001) and with coronary
calcification (mitral valve r  0.35, aortic valve r  0.28,
p  0.0001). Coronary artery and aorta calcification were
more strongly correlated (r  0.60, p  0.0001).
Unlike calcification of the coronary arteries or aorta, there
were few clinical predictors of the presence or extent of
valvular calcification. Whether by standard logistic regres-
sion with the presence or absence of calcification as the
dependent variable, or proportional odds logistic regression
(comparing the odds of having two vs. one vs. no calcified
valves), only dialysis vintage was significantly associated
with valvular calcification risk. Linear regression analysis in
the smaller subset of patients with valvular calcification
(aortic and/or mitral) demonstrated no significant correlates
(demographic, clinical or laboratory) of the valvular calcifi-
cation scores.
DISCUSSION
Herein we describe EBT findings in 205 adult patients
receiving maintenance hemodialysis. There was a high
prevalence of calcification of the coronary arteries, aorta and
cardiac valves, and though the range was wide, the majority
of patients showed coronary calcification to a degree far
greater than expected for age- and gender-matched individ-
uals in the normal population. Furthermore, the prevalence
of preexisting cardiovascular disease was proportional to the
severity of vascular calcification.
Table 4. Multivariable Linear Regression With Extent of
Coronary Calcification as Dependent Variable
Variable Parameter Estimate p Value
Intercept 6.717388
Age 0.211344 0.0003
Age squared 0.001359 0.0077
Female 0.587547 0.0167
Black race 0.586606 0.0539
Diabetes 0.616307 0.0153
Dialysis vintage 0.008350 0.0001
Calcium 0.529816 0.0013
Phosphorus 0.240085 0.0047
Overall model p value 0.0001, n  170 for subjects with non-zero coronary
calcification, parameter estimates per year age, per month vintage, per 1 mg/dl calcium
and phosphorus.
Table 5. Multivariable Linear Regression With Extent of Aortic
Calcification as Dependent Variable
Variable Parameter Estimate p Value
Intercept 5.575276
Age 0.252359 0.0040
Age squared 0.000950 0.2121
Female 0.044508 0.9036
Black race 1.462062 0.0015
Diabetes 0.323171 0.3896
Dialysis vintage 0.006576 0.0331
Phosphorus 0.244545 0.0621
PTH 0.001809 0.0647
Overall model p value 0.0001, N  164 for subjects with non-zero aortic
calcification, parameter estimates per year age, per month vintage, per 1 mg/dl
phosphorus, and per 1 pg/ml parathyroid hormone (PTH).
Table 2. Clinical Correlates of Coronary Artery
Calcification Score
0 1–400 401–1,000 >1,000 p Value
Previous MI (%) 6% 2% 10% 30% 0.0001
Angina (%) 9% 10% 19% 41% 0.0001
Known CAD (%) 3% 17% 26% 60% 0.0001
Any ASVD 14% 23% 50% 84% 0.0001
ASVD  atherosclerotic vascular disease; CAD  coronary artery disease; MI 
myocardial infarction.
Table 3. Clinical Correlates of Aortic Calcification Score
0
Tertile
1
Tertile
2
Tertile
3
p
Value
Claudication (%) 7% 7% 25% 25% 0.001
Aneurysm (%) 0% 0% 6% 5% 0.02
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Coronary artery calcium and cardiovascular disease.
Coronary calcium is a highly sensitive marker of underlying
atherosclerotic disease (18–20), and coronary calcification
has been shown to be associated with cardiovascular events
in individuals unaffected by renal disease (16,21,22). Mar-
golis et al. (23) reported that patients with coronary calci-
fication visualized by fluoroscopy during coronary angiog-
raphy had a five-year survival rate of 58% compared with
87% for patients without calcification. The negative prog-
nostic significance of coronary artery calcification appeared
to be independent of the severity of coronary luminal
obstruction seen on angiography. Detrano et al. (24)
showed that among 1,461 patients undergoing coronary
angiography, those with coronary calcium in more than one
vessel by EBT were 2.2 times more likely to suffer a
cardiovascular event than subjects with no calcified vessels.
Several additional reports of asymptomatic patients have
also indicated that the relative risk of coronary events is
significantly increased in the presence of coronary calcifica-
tion. Raggi et al. (16) demonstrated that an elevated age-
and gender-specific calcium score percentile was the most
powerful predictor of MI and death. Indeed, the EBT
calcium score adds incremental prognostic value above and
beyond other “traditional” risk factors for CAD (25).
Previous use of EBT in ESRD. Braun et al. (26) previ-
ously evaluated 49 ESRD patients with EBT imaging.
These investigators observed that the extent of coronary
calcification in ESRD was significantly greater than in
non-ESRD patients with established CAD. In 39 children
and young adults with ESRD, Goodman et al. (11) found
coronary artery calcification in 36%. Calcification was
clearly related to age (calcification in 0 of 23 patients 20
years, and 14 of 16 patients 20 to 30 years of age). Dialysis
vintage (time since initiation of dialysis), body mass index,
serum albumin, the calcium-phosphorus product and the
prescribed dose of oral calcium were also associated with
calcification. No multivariable analyses were conducted.
Our findings extend those of Braun et al. (26) and
Goodman et al. (11). With a larger cohort of adult hemo-
dialysis patients, we found that advanced age, male gender,
diabetes, vintage and the serum concentrations of calcium
and phosphorus were all significantly and independently
associated with the extent of coronary artery calcification.
There was also a trend toward increased calcification among
non-black compared with black subjects. There were no
significant associations among lipid levels, PTH, albumin,
or hemoglobin and the extent of coronary artery calcifica-
tion.
Study limitations. Misclassification bias is the major lim-
itation of this study. We may have missed significant
associations among certain laboratory variables and vascular
calcification, as a single baseline laboratory value may not
reflect the time-averaged exposure. Misclassification may
have lessened the strength of some of the significant
predictors of calcification, especially those that vary widely
day-to-day (e.g., serum phosphorus). The exclusion of
subjects with uncontrolled diabetes and/or hypertension
probably resulted in a study sample with less severe overall
calcification than an unselected hemodialysis population.
The study sample was also biased by the exclusion of
subjects with severe hyperphosphatemia. Their inclusion
might have strengthened the association between serum
phosphorus and the extent of calcification.
Obviously, the cross-sectional design does not allow
causal inference. However, since serum phosphorus and
calcium have been directly correlated with mortality in
patients with ESRD (8), these findings support the hypoth-
esis that cardiovascular calcification might be modifiable
based on the degree to which one could control or prevent
dysregulation of mineral metabolism associated with ESRD
and dialysis therapy. The absence of an association between
lipids and cardiovascular calcification does not necessarily
indicate that dyslipidemia is of less importance in this
population than in others, because confounding by nutri-
tional status, as well as inflammatory and liver diseases may
mask such an association.
Summary. Vascular and valvular calcifications are common
and severe in the adult hemodialysis population. Prospective
observational studies, and clinical trials aimed at modifying
the course of calcification, will be required to better under-
stand the link between calcification and cardiovascular
outcomes in ESRD and to determine whether renal disease,
dialysis, or both, are responsible for the excessive degree of
calcification in this population.
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